Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes

Clarence Hale; Minghan Wang

doi:10.2174/138955708784567421

Development of 11beta-HSD1 inhibitors for the treatment of type 2 diabetes

Mini Rev Med Chem. 2008 Jun;8(7):702-10. doi: 10.2174/138955708784567421.

Authors

Clarence Hale¹, Minghan Wang

Affiliation

¹ Department of Metabolic Disorders, Amgen Inc., One Amgen Center Drive, Mail Stop 29-1-A, Thousand Oaks, CA 91320, USA.

PMID: 18537725
DOI: 10.2174/138955708784567421

Abstract

Glucocorticoid action is linked to the development of obesity and insulin resistance. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) has been proposed as a strategy to suppress glucocorticoid action in a tissue-specific manner. A large variety of 11beta-HSD1 inhibitor classes are under investigation by the pharmaceutical industry to treat type 2 diabetes and obesity.

Publication types

Review

MeSH terms

11-beta-Hydroxysteroid Dehydrogenase Type 1 / antagonists & inhibitors
11-beta-Hydroxysteroid Dehydrogenase Type 1 / chemistry
Diabetes Mellitus, Type 2 / drug therapy*
Enzyme Inhibitors / chemistry
Enzyme Inhibitors / pharmacology
Humans
Hypoglycemic Agents / chemistry*
Hypoglycemic Agents / therapeutic use*

Substances

Enzyme Inhibitors
Hypoglycemic Agents
11-beta-Hydroxysteroid Dehydrogenase Type 1
HSD11B1 protein, human